Hims & Hers (HIMS) stock rallied nearly 50% this morning after Danish pharmaceutical behemoth Novo Nordisk (NVO) dropped its high-stakes GLP-1 lawsuit against the American telehealth firm. HIMS now looks headed to challenge its 50-day moving average (MA), with a clear break above the $25 level expected to accelerate upward momentum in the near term.
Still, there’s reason for prudent investors to consider unloading Hims & Hers shares today, even though they’re still down about 37% versus their year-to-date high.
